Chime Biologics Resumes Full-Scale Operation to Ensure Manufacturing Services

According to the approval of the Epidemic Prevention and Control Headquarters of Wuhan East Lake New Technology Development Zone, Chime Biologic (formerly Xikang) has been fully resumed on March 20, 2020. Chime Biologics strictly in accordance with the epidemic prevention requirements, make an epidemic prevention and control plan with dynamic updates and earnestly implement the relevant work arrangement from personnel management, factory management, meeting management, commuting, dining management to cleaning and disinfection. The full-scale implementation of management measures help to ensure the health and safety of employees and project progress of clients.

Previously, in order to mitigate the impact of the epidemic, Chime Biologics resolutely implemented the prevention and control requirements by the Government and in the meantime constantly made preparations for the full resumption of work:

Actively providing employees with phased work certificates and passes, doing factory engineering inspection and equipment maintenance 24 hours a day, uninterrupted purchase negotiation and receiving of raw materials, uninterrupted project sample testing and project startup, continuously online communicating with customers and discussing expansion plan. After we getting the resumption of work approval, point – to – point buses are arranged to help the staff return to work. After full resumption of work, Chime Biologics will further improve its operational capacity, accelerate the expansion of capacity as planned, and better provide customers with one-stop CDMO services, while continuing to follow the epidemic prevention and control.

One of Chime Biologics partners has announced the successful IND application of his drug against Covid-19 in the United States and will carry out clinical research to treat patients with severe and critical Covid-19 associated cytokine storms in USA and other serious countries, which is an independently developed neutralizing antibody against human granulocyte macrophage colony stimulating factor (GM-CFS). GM-CFS is a cytokine that plays a key role in acute and chronic inflammation. Chime Biologics provides customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. Two post-clinical projects will ensure the supply of clinical samples and help the drug speed-to-market.

“Although the epidemic has had a great impact on the whole country, especially in Wuhan, I don’t think CDMO business of Chime Biologics will be adversely affected. At present, we have fully resumed to our work. We will continue to provide efficient and high-quality services for customers, and at the same time actively communicate with suppliers to deal with the global supply of raw materials, so as to ensure the rapid progress of customers’ projects to the greatest extent.” Said Dr. Peter Pang, general manager of Chime Biologics.


Chime Biologics, a China-based, world-class Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide one stop comprehensive solution supporting our customers from early-stage biopharmaceutical development through late-stage clinical and commercial manufacturing, catering to the evolving needs of the dynamic biopharmaceutical industry. We pledge to make world-class biopharmaceuticals affordable and accessible to all patients globally through manufacturing innovation, and empowering therapeutic advancement for improvement of human health.

With our State-of-the-art facility and in-house world class expert team, we are committed for excellence upholding highest degree of integrity. Our World’s first GE KuBio facility is located at Wuhan’s BioLake biotech industry development zone of China, with clear path to expand the total capacity up to 140,000+ in the near future. For more information on Chime Biologics, please visit